With the widespread spread of the Omicron Corona virus strain, the specialists of the Barakat Pharmaceutical Group produced a special vaccine for this strain.
Barakat Pharmaceutical Group, with scientific observations and consultation with experts in this field, has completed the production of a specific vaccine of Amicron one month after the detection of this virus in the country and has performed the study of the updated vaccine on an animal model. Preliminary results of these studies indicate the 100% neutralization of the Amicron strain by the new vaccine and its safety in animal studies.
Due to the unprecedented speed of Amicron release in the community and the promising results of animal studies, the company has started mass production of vaccines for this field and has proposed a proposed protocol for conducting a clinical study of the vaccine for decision to the FDA and Ethics Committee.
The emergence of the Amicron strain and the publication of scientific reports that it stems from escaping the antibodies produced by current vaccines and reducing their effectiveness have raised major concerns. Also, in January, the World Health Organization (WHO) issued a policy announcement repeating the dose of booster doses as a non-sustainable approach and advised vaccine manufacturers to update their vaccines according to the prevailing strains.